Chicago Partners Investment Group LLC Boosts Stock Holdings in Illumina, Inc. $ILMN

Chicago Partners Investment Group LLC raised its position in Illumina, Inc. (NASDAQ:ILMN) by 85.6% in the second quarter, Holdings Channel reports. The institutional investor owned 5,200 shares of the life sciences company’s stock after purchasing an additional 2,398 shares during the period. Chicago Partners Investment Group LLC’s holdings in Illumina were worth $544,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ILMN. Vanguard Group Inc. increased its stake in shares of Illumina by 3.5% in the 1st quarter. Vanguard Group Inc. now owns 16,371,662 shares of the life sciences company’s stock valued at $1,298,928,000 after purchasing an additional 558,243 shares in the last quarter. WCM Investment Management LLC increased its position in shares of Illumina by 5.9% in the second quarter. WCM Investment Management LLC now owns 4,426,471 shares of the life sciences company’s stock valued at $419,585,000 after buying an additional 247,460 shares in the last quarter. Corvex Management LP increased its position in shares of Illumina by 125.2% in the first quarter. Corvex Management LP now owns 3,829,608 shares of the life sciences company’s stock valued at $303,841,000 after buying an additional 2,129,449 shares in the last quarter. Brown Advisory Inc. increased its position in shares of Illumina by 52.1% in the first quarter. Brown Advisory Inc. now owns 2,909,228 shares of the life sciences company’s stock valued at $230,818,000 after buying an additional 996,589 shares in the last quarter. Finally, AQR Capital Management LLC increased its position in shares of Illumina by 361.7% in the first quarter. AQR Capital Management LLC now owns 2,121,585 shares of the life sciences company’s stock valued at $165,484,000 after buying an additional 1,662,093 shares in the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Analyst Upgrades and Downgrades

ILMN has been the subject of several research reports. Evercore ISI cut their price objective on Illumina from $135.00 to $132.00 and set an “outperform” rating for the company in a research note on Tuesday, October 7th. Daiwa Capital Markets lowered shares of Illumina from an “outperform” rating to a “neutral” rating and set a $94.00 target price for the company. in a report on Tuesday, August 12th. Scotiabank lowered shares of Illumina from a “sector outperform” rating to a “sector perform” rating and set a $125.00 target price for the company. in a report on Friday, July 11th. Citigroup cut shares of Illumina from a “hold” rating to a “strong sell” rating and dropped their price objective for the company from $85.00 to $80.00 in a research note on Wednesday, July 9th. Finally, Canaccord Genuity Group increased their price target on shares of Illumina from $99.00 to $105.00 and gave the company a “hold” rating in a research note on Friday, August 1st. Five research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $115.25.

Illumina Trading Down 1.7%

NASDAQ ILMN opened at $97.23 on Thursday. The firm has a 50 day simple moving average of $98.17 and a 200-day simple moving average of $91.11. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.41 and a current ratio of 1.81. Illumina, Inc. has a one year low of $68.70 and a one year high of $156.66. The firm has a market cap of $14.94 billion, a price-to-earnings ratio of 12.31, a PEG ratio of 2.44 and a beta of 1.40.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, July 31st. The life sciences company reported $1.19 EPS for the quarter, beating the consensus estimate of $1.02 by $0.17. The business had revenue of $1.06 billion during the quarter, compared to analyst estimates of $1.12 billion. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The business’s revenue for the quarter was down 4.8% compared to the same quarter last year. During the same quarter last year, the firm posted $0.36 earnings per share. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. Equities research analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.